Spectrum Pharma (SPPI): Cutting PT After apaziquone Rejection - RBC

September 15, 2016 7:34 AM EDT
Get Alerts SPPI Hot Sheet
Price: $4.12 +2.23%

Rating Summary:
    8 Buy, 2 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 27 | New: 28
Trade SPPI Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

RBC Capital analyst, Adnan Butt, reiterated his Outperform rating on shares of Spectrum Pharmaceuticals (NASDAQ: SPPI) but reduced his price target to $10 from $11 after apaziquone was voted down.

The FDA’s cancer drug advisory committee voted against apaziquone approval. The panel found apaziquone promising due to the unmet need, however, statistical analyses were the hurdle and something the FDA had repeatedly emphasized. Since the unmet need is there, the end market is large and the space remains unchanged, the analyst believes the opportunity is worth pursuing as a third Phase 3 started in 2015.

For an analyst ratings summary and ratings history on Spectrum Pharmaceuticals click here. For more ratings news on Spectrum Pharmaceuticals click here.

Shares of Spectrum Pharmaceuticals closed at $5.04 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

RBC Capital

Add Your Comment